Ajanta Pharma Limited (India) holds 4 active US FDA Type II Drug Master Files and 2 inactive, has DMF or CEP filings on record for 5 active ingredients and is linked to 1 FDA-registered manufacturing site. 8 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Ajanta Pharma Limited: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/ajanta-pharma-limited

Overview

Ajanta Pharma Limited is a leading Indian pharmaceutical company that specializes in the development, manufacture, and marketing of a wide range of branded and generic formulations. With a strong presence in over 30 countries, the company is known for its focus on quality, innovation, and sustainability across therapeutic areas.

Core services & business areas

ManufacturingMarketingResearch and Development

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Ajanta Pharma Limited holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Ajanta Pharma Limited holds 4 active (6 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • VORICONAZOLE USPActive2023-05-30
  • RANOLAZINEActive2023-02-06
  • DULOXETINE HYDROCHLORIDE USPActive2022-09-30
  • VALGANCICLOVIR HYDROCHLORIDE USP (Crystalline)Active2021-10-22
  • CEFADROXIL USPInactive1999-06-14
  • MANUFACTURED SITE, FACILITIES, PERSONNEL AND OPERATING PROCEDURES IN MAHARASHTRA, INDIAInactive1997-03-05

Registered manufacturing sites (1)

Physical sites registered with the US FDA and resolved to Ajanta Pharma Limited, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

8 FDA enforcement records linked to this company.

  • recall — Class II2026-05-13

    CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

  • recall — Class II2026-05-13

    CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

  • recall — Class II2026-05-13

    CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

  • 4832026-04-21

    Cleaning / Sanitizing / Maintenance

  • 4832026-04-21

    SOPs not followed / documented

  • 4832026-04-21

    Equipment Design, Size and Location

  • 4832026-04-21

    Investigations of discrepancies, failures

  • 4832026-04-21

    Procedures not in writing, fully followed

For suppliers

Is this Ajanta Pharma Limited?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.